Loading...
01/10 17:30
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. Positives include a new partnership with PATHOMIQ and product launches. However, financials reveal a revenue decline in key areas, reduced guidance, and regulatory challenges. The Q&A highlights management's lack of clarity on critical issues like EMR integration and NCCN guidelines. The market cap suggests moderate sensitivity, but the negatives, especially the reduced guidance and GeneSight's headwinds, outweigh the positives, predicting a negative stock movement of -2% to -8%.
Revenue $196,000,000, a decline of 3% year over year due to softness in GeneSight and MiRisk tests, offset by growth in prenatal and oncology tests. Excluding certain impacts, revenue grew 5% year over year.
Prenatal Testing Revenue Increased by 11% year over year, driven by strong demand for carrier screening and NIPS tests.
GeneSight Revenue $31,000,000, down 20% year over year, primarily due to UnitedHealthcare’s coverage policy change.
Hereditary Cancer Revenue Decreased by 2% year over year, with positive growth in oncology but challenges in the hereditary cancer segment.
MiRisk Test Volume Growth 11% year over year, indicating strong demand in the oncology channel.
Gross Margin 69%, an increase of 50 basis points year over year, reflecting lab efficiencies.
Adjusted Operating Expenses Increased minimally year over year, balancing R&D investment with cost controls.
Income Tax Benefit $29,300,000 recognized in Q1, expected to result in approximately $13,000,000 of cash tax refunds.
Adjusted EBITDA Near breakeven for Q1, indicating a challenging cash flow environment.
Cash and Cash Equivalents $92,000,000 at the end of Q1, with an additional $42,000,000 available under the revolver.
Annual Revenue Guidance Updated to $807,000,000 to $823,000,000, reflecting a $35,000,000 reduction primarily due to GeneSight volume expectations.
Adjusted OpEx Guidance Revised to between $555,000,000 and $565,000,000, reflecting deliberate steps to reduce discretionary spending.
Adjusted EPS Guidance Expected to be between a loss of $0.02 and a gain of $0.02 for full year 2025.
Adjusted EBITDA Guidance Targeted between $19,000,000 and $27,000,000 for the full year.
New Product Launches: On track to launch 'First Gene', a combined carrier screening and NIPS assay within the next couple of months.
AI-enabled Prolaris Test: Expected to launch by the end of 2025 to support clinical decisions at the time of biopsy.
PreciseMRD Test: First MRD test expected to launch in the first half of 2026.
Market Expansion: Continued traction in prenatal testing with 11% revenue growth year over year.
GeneSight Test Volume: GeneSight test volume grew 2% year over year despite challenges from UnitedHealthcare's policy change.
Women's Health Revenue: Women's health revenue increased by 4% year over year, driven by strong prenatal testing performance.
Operational Efficiencies: Identified workflow improvements to address EMR integration challenges across 15+ vendors.
Cost Reduction: Deliberate steps taken to reduce overall projected spending by $25 million while prioritizing high-value product development.
Strategic Shifts: Focus on oncology as the cornerstone of Myriad's strategy, with plans to enhance execution and simplify operations.
Leadership Changes: New leadership appointments to strengthen the team and improve execution capabilities.
Revenue Decline: The company reported a 3% year-over-year decline in revenue, primarily due to underperformance in GeneSight and MiRisk tests, which were impacted by UnitedHealthcare's policy changes.
GeneSight Test Volume: GeneSight test volume growth was only 2% year-over-year, significantly affected by a $10 million revenue headwind from UnitedHealthcare's coverage policy change.
Operational Challenges: The integration of EMR systems across various vendors has been slower than expected, causing disruptions in workflow and impacting the volume of unaffected hereditary cancer testing.
Financial Guidance Reduction: The company lowered its 2025 revenue guidance by $35 million, attributing this to reduced expectations for GeneSight and slower ramp-up in unaffected hereditary cancer testing.
Cost Management: Myriad Genetics is taking deliberate steps to reduce overall spending by $25 million while prioritizing investments in high-value product development.
Market Competition: The company faces competitive pressures in the oncology market, particularly with GeneSight, which is sensitive to market dynamics and payer coverage.
Economic Factors: There are concerns about potential recessionary impacts on patient payments and prescription patterns, which could further affect revenue.
Regulatory Issues: The company is navigating complex regulatory environments, particularly with respect to payer coverage and the evolving NCCN guidelines.
Supply Chain Challenges: The integration of new products and EMR systems is causing delays and challenges in scaling operations effectively.
New Product Launches: On track to launch 'First Gene', a combined carrier screening and NIPS assay within the next couple of months. Launch of 'PreciseMRD' is expected in the first half of 2026, with clinical data presented at ASCO in June. Launch of AI-enabled 'Prolaris' test by the end of this year.
Cost Management: Deliberate steps to reduce overall projected spending while prioritizing investments in driving 2025 revenue and high-value new product development.
Oncology Focus: Oncology remains the cornerstone of Myriad's strategy, focusing on the continuum of cancer care from screening to therapy selection and monitoring.
2025 Revenue Guidance: Updated annual revenue guidance lowered to $807 million to $823 million, reflecting a $35 million reduction from prior midpoint.
Gross Margin Guidance: Expected gross margin range of 68.5% to 69.5% for 2025.
Operating Expenses Guidance: Adjusted OpEx guidance set between $555 million and $565 million, reflecting a $25 million reduction from prior midpoint.
Adjusted EPS Guidance: Adjusted EPS expected to range from a loss of $0.02 to a gain of $0.02 for the full year 2025.
Adjusted EBITDA Guidance: Targeting adjusted EBITDA of between $19 million and $27 million for 2025.
Shareholder Return Plan: The company has updated its financial guidance for 2025, projecting annual revenue of $807,000,000 to $823,000,000, reflecting a reduction of $35,000,000 from prior estimates. This adjustment is primarily due to a $10,000,000 revenue headwind from UnitedHealthcare's coverage policy change affecting GeneSight, along with slower than anticipated volume growth in unaffected hereditary cancer testing. The company is also taking deliberate steps to reduce overall projected spending by $25,000,000 while prioritizing investments in high-value new product development.
Share Repurchase Program: None
Dividend Program: None
The earnings call reveals strong performance with raised revenue and EBITDA guidance, new product launches, and strategic partnerships. Despite some operational challenges, management's optimistic outlook, particularly in prenatal and cancer diagnostics, suggests potential growth. The Q&A highlights market expansion and improved customer workflows, reinforcing positive sentiment. However, unclear responses on ASP assumptions and reimbursement timelines introduce some uncertainty, slightly tempering the overall positive outlook.
The earnings call presents a mixed picture. Financial performance shows improvement, with increased adjusted gross margin and EBITDA. However, the lowered revenue guidance and unresolved issues like SneakPeek and unclear management responses create uncertainties. The strategic focus on oncology and partnerships is promising but lacks immediate impact. Overall, the sentiment is neutral with potential for future growth, but current uncertainties and guidance adjustments balance out the positives.
The earnings call reveals several negative factors: a 3% revenue decline, a significant impact from UnitedHealthcare's policy change on GeneSight, and cash burn issues. Despite some positives like prenatal revenue growth and increased gross margins, the lack of a share repurchase program and unclear management responses in the Q&A section further contribute to uncertainty. The market cap of approximately $2.2 billion suggests moderate sensitivity to these issues, leading to an overall negative sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
